Health ❯ Healthcare ❯ Medical Research ❯ Gene Therapy

Huntington's Disease

uniQure Shares Plummet After AMT-130 Misses Pre-Specified Statistical Goal

Citing possible control-group attrition bias, uniQure is relying on a stronger 36-month dataset in its FDA filing.

FDA Agrees Three‑Year Phase I/II Data Can Support uniQure’s AMT‑130 Accelerated BLA

FDA Meeting Minutes Undercut uniQure’s Plan to File Huntington’s Gene Therapy for Approval

Gene Therapy Slows Huntington’s Progression by 75% in Early Trial, uniQure Says